AIRLINK 80.50 Increased By ▲ 1.09 (1.37%)
BOP 5.29 Decreased By ▼ -0.04 (-0.75%)
CNERGY 4.38 No Change ▼ 0.00 (0%)
DFML 35.00 Increased By ▲ 1.81 (5.45%)
DGKC 76.49 Decreased By ▼ -0.38 (-0.49%)
FCCL 20.45 Decreased By ▼ -0.08 (-0.39%)
FFBL 32.15 Increased By ▲ 0.75 (2.39%)
FFL 9.71 Decreased By ▼ -0.14 (-1.42%)
GGL 10.20 Decreased By ▼ -0.05 (-0.49%)
HBL 117.80 Decreased By ▼ -0.13 (-0.11%)
HUBC 134.85 Increased By ▲ 0.75 (0.56%)
HUMNL 7.04 Increased By ▲ 0.04 (0.57%)
KEL 4.58 Decreased By ▼ -0.09 (-1.93%)
KOSM 4.70 Decreased By ▼ -0.04 (-0.84%)
MLCF 37.25 Decreased By ▼ -0.19 (-0.51%)
OGDC 136.60 Decreased By ▼ -0.10 (-0.07%)
PAEL 23.00 Decreased By ▼ -0.15 (-0.65%)
PIAA 27.04 Increased By ▲ 0.49 (1.85%)
PIBTL 6.96 Decreased By ▼ -0.04 (-0.57%)
PPL 113.50 Decreased By ▼ -0.25 (-0.22%)
PRL 27.70 Increased By ▲ 0.18 (0.65%)
PTC 14.82 Increased By ▲ 0.07 (0.47%)
SEARL 56.99 Decreased By ▼ -0.21 (-0.37%)
SNGP 67.00 Decreased By ▼ -0.50 (-0.74%)
SSGC 11.04 Decreased By ▼ -0.05 (-0.45%)
TELE 9.25 Increased By ▲ 0.02 (0.22%)
TPLP 11.60 Increased By ▲ 0.04 (0.35%)
TRG 72.75 Increased By ▲ 0.65 (0.9%)
UNITY 25.55 Increased By ▲ 0.73 (2.94%)
WTL 1.36 Decreased By ▼ -0.04 (-2.86%)
BR100 7,558 Increased By 31.8 (0.42%)
BR30 24,667 Increased By 17.4 (0.07%)
KSE100 72,201 Increased By 229.7 (0.32%)
KSE30 23,837 Increased By 87.9 (0.37%)
World

Norway will not offer AstraZeneca COVID-19 vaccine to people over 65

  • The FHI said there had been few participants above the age of 65 in the trial conducted by AstraZeneca, meaning there was a lack of documentation as to the effect of the vaccine on older age groups.
Published February 4, 2021

OSLO: Norway will not offer the AstraZeneca vaccine against COVID-19 to individuals over the age of 65, the Norwegian Institute of Public Health (FHI) said on Thursday, making it the latest European country to restrict its use.

So far, some 135,000 individuals in Norway have received their first dose against the disease and some 35,000 have received their second shot, from vaccines made by Moderna and from a partnership between Pfizer and BioNTech, the agency said.

The FHI said there had been few participants above the age of 65 in the trial conducted by AstraZeneca, meaning there was a lack of documentation as to the effect of the vaccine on older age groups.

The Nordic country has 5.4 million inhabitants.

Comments

Comments are closed.